Troplastim®
Таблетки, покрытые пленочной оболочкойHaemostatic agent
Indications
Treatment of thrombocytopenia in adult patients with chronic liver disease in whom the procedure is planned; with primary chronic immune thrombocytopenia and unsatisfactory response to previous therapy.
Contraindications
Hypersensitivity to avatrombopag; thrombocytopenia in patients with myelodysplastic syndrome (MDS); paediatric and adolescent age less than 18 years.
Caution
In patients with chronic liver disease; in patients with known risk factors for thromboembolism and in patients previously taking avatrombopag; in concomitant use with moderate or strong dual inhibitors of CYP2C9 and CYP3A4/5 isoenzymes, or of CYP2C9 isoenzyme alone (e.g. fluconazole) in patients with chronic liver disease and chronic immune thrombocytopenia; in concomitant use of avatrombopag with interferon drugs, GCS, danazol, dapsone, IV immunoglobulin and with moderate or strong dual inducers of CYP2C9 and CYP3A4/5 isoenzymes, or CYP2C9 isoenzyme alone; if avatrombopag treatment is discontinued against the background of anticoagulants or antiplatelet agents.
Usage
For oral administration.
The single dose is 20 mg. Depending on the initial platelet count, the daily dose is 40-60 mg, frequency of administration - 2-3 times/day. Due to limited information avatrombopag should be taken for no more than 5 days.
Administration of avatrombopag should be started 10-13 days before the planned procedure. The procedure should be performed 5-8 days after the last dose of avatrombopag.
Have questions? Contact Us
Drugs in the category Therapy
Has contraindications. Needs specialist overview.